We hypothesized that the depletion of NRF1 in both secondary breast cancer cell lines grown in vitro and xenograft tumor cells would overcome this potential resistance mechanism and confer sensitivity to the irreversible proteasome inhibitor carfilzomib, despite its expected rapid clearance from the blood. This evidence concerns the gene NRF1 and breast carcinoma.